MONTREAL--(Business Wire / Korea Newswire)--C3i Center Inc (C3i) announced it has received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies, making C3i the first CDMO in Canada to achieve this milestone.

The approval follows an inspection by the cell and gene therapy experts from Health Canada. The DEL approval recognizes C3i as having industry-leading expertise, regulatory know-how, and strong quality standards.

“The C3i team worked hard to meet the requirements of a DEL and are proud that we received approval from Health Canada to commercially manufacture cell therapies.” - Louisa Petropoulos, CEO of C3i. “We are excited to be the first CDMO in Canada to reach this milestone, and there is more to come. Our goal is to manufacture cell and gene therapies for the global market. We expect to have the European Medicines Agency (EMA) conduct their inspection later this fall.”

C3i supports its clients in process development, scale-up and manufacturing for phase 1 to phase 3 clinical trials, as well as commercial cell and gene-modified cell therapies. C3i continues to expand its capabilities to include the production of viral vectors, exosomes, and other autologous and allogeneic cellular therapies.

About C3i Center Inc

C3i is a full-service, in-house CDMO with a vision to make life-saving cell and gene therapies available to everyone who needs them. C3i provides services to biotechnology companies, academic research groups, and pharmaceutical companies, supporting the advancement and commercialization of innovative technologies. C3i’s dedicated team is focused on providing clients with tailored services to meet their specific needs, expediting their innovative pipeline from development to commercial. C3i prides itself on delivering on-time, cost-efficient quality results. In-house services include phase-appropriate quality control testing, biomarker discovery, immune monitoring and diagnostic testing with College of American Pathologists (CAP)-accredited laboratories.

To learn more about who we are, visit www.c3icenter.com and for business inquiries, please contact our VP of Business Development, Sandra Donaldson, at [email protected].

View source version on businesswire.com: https://www.businesswire.com/news/home/20240620081082/en/

View Korean version of this release Contact C3i Center Inc
[email protected]
This news is a press release provided by C3i Center Inc. Korea Newswire follows these editorial guidelines. C3i Center Inc News ReleasesSubscribeRSS C3i 센터, 캐나다 최초로 CDMO로서 세포 치료 의약품의 상업적 생산 위한 의약품 제조 허가 승인 획득 C3i 센터(Center Inc, 이하 C3i)가 세포 치료제를 상업적으로 생산할 수 있는 의약품 제조 허가(Drug Establishment License, DEL)의 형태로 규제 당국의 승인을 받아 캐나다에서 이러한 이정표를 달성한 최초의 위탁개발생산(CDMO) 기업이 됐다고 발표했다. 이번 승인은 캐나다 보건부(Health Canada)의 세포... 6월 21일 11:25 More News Health Biotechnology Pharmaceutical Certification Overseas C3i Center Inc All News Releases 